PureTech HealthPRTCY +1.49%62 Quick Ratio is 6.59 as of Dec. 2025, which is 192% above its 10-year median of 2.26. GuruFocus rates PRTCY with a GF Score™ of 62/100 and a GF Value™ of $70.09 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,417 Biotechnology companies, PureTech Health ranks better than 67.75% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. PureTech Health's quick ratio for the quarter that ended in Dec. 2025 was 6.59.
PureTech Health has a quick ratio of 6.59. It generally indicates good short-term financial strength.
The historical rank and industry rank for PureTech Health's Quick Ratio or its related term are showing as below:
PRTCY'
s Quick Ratio Range Over the Past 10 Years
Min: 0.72 Med: 2.26 Max: 9.33
Current: 6.59
During the past 13 years, PureTech Health's highest Quick Ratio was 9.33. The lowest was 0.72. And the median was 2.26.
PRTCY's Quick Ratio is ranked better than 67.75% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs PRTCY: 6.59
PureTech Health (OTCPK:PRTCY) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
PureTech Health Quick Ratio Related Terms
PureTech Health Quick Ratio Historical Data
* Premium members only.
The historical data trend for PureTech Health's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PureTech Health's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's Quick Ratio distribution charts can be found below:
* The bar in red indicates where PureTech Health's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
PureTech Health's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health (PRTCY) has a Quick Ratio of 6.59 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on PureTech Health and its competitors. This is 192% above median its historical median of 2.26. Over the past decade, PureTech Health's Quick Ratio has ranged from 0.72 to 9.33. According to the industry distribution chart, PureTech Health ranks #457 out of 1417 companies in the Biotechnology industry, placing it in the top 32.3%.
Is PureTech Health's Quick Ratio too high?
PureTech Health's current Quick Ratio of 6.59 is 192% above median its 10-year median of 2.26. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 9.33. The Biotechnology industry median Quick Ratio is 3.60. PureTech Health's value of 6.59 is 83.1% above this industry median. Based on the distribution chart, PureTech Health ranks #457 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #457 out of 1417 companies for Quick Ratio. This puts PureTech Health in the upper half of its industry. The industry median Quick Ratio is 3.60. PureTech Health's value of 6.59 is 83.1% above this benchmark. Historically, PureTech Health's own Quick Ratio has ranged from 0.72 to 9.33 over the past decade. While the company's 10-year median is 2.26 vs. the industry median of 3.60, PureTech Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PureTech Health's current Quick Ratio of 6.59 is 83.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on PureTech Health and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PureTech Health's current Quick Ratio is 6.59, which is 192% above median its own 10-year median of 2.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (PRTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $70.09, compared to a current price of $17.54 — trading 75% below its estimated fair value. The current Quick Ratio is 6.59, which is 192% above median its 10-year median of 2.26 and 83.1% above the Biotechnology industry median of 3.60. PureTech Health's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For PureTech Health (PRTCY), the current Quick Ratio is 6.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (PRTCY) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for PRTCY:
Quick Ratio: 6.59 (192% above median its 10-year median of 2.26)
GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
Industry Position: 83.1% above the Biotechnology median (#457 of 1417)
No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score
Get the complete analysis for PRTCY
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRTCY has been successfully added to your 
